CATALENTAI
"CATALENTAI" is a word mark owned by R.P. Scherer Technologies, LLC, filed at the USPTO on January 20, 2026. It has been allowed and covers class 42 (Computer and Scientific Services).
- Status
- Allowed
- Since August 25, 2026
- Filed
- January 20, 2026
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 99603372
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 1 class
Who owns CATALENTAI
The owner and representative on file with the office.
Owner
R.P. Scherer Technologies, LLC
Bridgewater, United States
Representative
Vanessa A. Ignacio, Esq.
Lowenstein Sandler LLP
What the mark covers
The products and services CATALENTAI is filed for, grouped by Nice class.
Software as a service (SAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for investigating, resolving deviation life cycle management, root cause analysis management, deviation tracking and reporting management, audit management, change control management, complaint and investigations management, and product annual review management; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for providing quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management, risk assessment, and root cause analysis; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management in regulated manufacturing environments; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for workflow automation of deviation lifecycle processes, namely, initiation, review, approval, corrective and preventive actions (CAPA), and closure; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for audit preparation and support, namely, compiling compliance documentation, and generating audit ready reports; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for change control management, namely, initiating, routing, approving, and implementing changes; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for complaints handling and investigations support, namely, intake, triage, root cause analysis, and corrective and preventive actions (CAPA); Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for product annual review support, namely, aggregating production and quality data, trend analysis, and generating annual product review reports; Pharmaceutical drug development services; Pharmaceutical research and development; Product development in the field of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, vitamins, medicines, pharmaceutical packaging and drug delivery technologies; Research and development of new products for others; Product development consultation; Scientific research consulting in the field of pharmaceuticals and biopharmaceuticals; Technology consultation in the field of pharmaceuticals and new drug development; Custom design and development of chemical reagents and biochemical assays; Development of pharmaceuticals for cell and gene therapies; Research and development and consultation related thereto in the field of over-the-counter drugs; Research and development in the field of pharmaceutical preparations and products for cell therapy, gene therapy, and beauty care; Scientific research consulting; Technology consultation in the field of new drug development for the pharmaceutical industry; Technology consultation in the field of pharmaceutical drug delivery and dosage technologies; Scientific research consulting in the field of pharmaceutical drug delivery and dosage technologies; Testing of pharmaceuticals
What has happened so far
Steps recorded by the USPTO, newest first.
- Noa e-mailed - sou required from applicant
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Assigned to examiner
- New application office supplied data entered
- Application filing receipt mailed
- New application entered
About CATALENTAI
Who owns the trademark "CATALENTAI"?
The USPTO trademark "CATALENTAI" (application 99603372) is owned by R.P. Scherer Technologies, LLC.
What is the status of "CATALENTAI"?
Its status at the USPTO is: allowed.
Get this data via the API
Everything on this page comes from the Signa API. Pull CATALENTAI and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2b8e-c58f-76dc-b031-7fe6ad91d6ee
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2b8e-c58f-76dc-b031-7fe6ad91d6ee",
"object": "trademark",
"mark_text": "CATALENTAI",
"status": {
"primary": "pending",
"stage": "allowed"
},
"office_code": "US",
"application_number": "99603372",
"filing_date": "2026-01-20",
"nice_classes": [
42
],
"owners": [
{
"name": "R.P. SCHERER TECHNOLOGIES, LLC",
"entity_id": null
}
]
}